News Search Results
Dec 03, 2025, 05:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Lawrence He, CEO, Rxilient.About Formosa Pharmaceuticals, Inc.Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®),
More news about: Formosa Pharmaceuticals Inc.,
Dec 03, 2025, 04:01 ET CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 Paris as the New Global Headquarter Opens
Dec. 3, 2025 /PRNewswire/ -- At the 30th milestone edition of Food Ingredients Europe 2025, the leading Chinese biotechnology company CABIO showcases its comprehensive nutritional ingredients portfolio while simultaneously announcing the official opening of its new Global
More news about: CABIO Biotech (Wuhan) Co, Ltd
Dec 02, 2025, 19:43 ET Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
(aflibercept-boav), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Dec 02, 2025, 18:48 ET Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
(including as a director of Invea Therapeutics, which is studying transformational precision medicines) and direct experience in delivering high-premium biotechnology transactions that is conspicuously absent from the current Board and is essential to evaluating Neuphoria's remaining pipeline and partnership opportunities.
More news about: Lynx1 Capital Management LP
Dec 02, 2025, 16:40 ET New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
LinkedIn. About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Dec 02, 2025, 14:00 ET Blood Cancer United, formerly The Leukemia & Lymphoma Society, Announces New Funding for Lifesaving Cancer Breakthroughs
diagnostic strategies and therapeutic options for follicular lymphoma.Auron Therapeutics, a Massachusetts-based clinical-stage biotechnology company, uses AI and machine learning to streamline and accelerate drug development. This speeds up finding new drug targets, the safest and most
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Dec 02, 2025, 13:44 ET Biodegradable Industrial Polymers for Circular Economy Applications Market worth USD 48.56 BN by 2032 | Credence Research
assessment indicates a highly dynamic and innovation-driven marketplace featuring global biopolymer producers, industrial consortiums, emerging biotechnology firms, and circular economy solution providers. Leading companies are increasingly investing in R&D partnerships, green chemistry innovation,
More news about: Credence Research Inc.
Dec 02, 2025, 10:30 ET AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)
CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- AOB Pharma, Inc. ("AOBiome"), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus,
More news about: AOBiome Therapeutics
Dec 02, 2025, 10:07 ET Katalyze AI Appoints Chief AI Officer to Advance Agentic AI Capabilities in Pharmaceutical Manufacturing
from it, and enable real-time decision making in pharmaceutical manufacturing.As a co-founder of Deep Genomics, one of the AI pioneers in biotechnology, he led the development of the core scientific computing platform, GenomeKit, for genomic analysis and developed deep learning models for splicing
More news about: Katalyze AI
Dec 02, 2025, 09:53 ET Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months
www.OSR-Holdings.com.About Vaximm AGVaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary orally administered T-cell vaccination platform harnesses live,
More news about: OSR Holdings
Dec 02, 2025, 09:05 ET Flywheel Launches Validated Imaging Solution to Accelerate Decision-Making Across the Clinical Trial Ecosystem
automating research workflows and preparing data for AI development. Flywheel's comprehensive solution is designed to allow pharmaceutical and biotechnology companies, academic medical centers, AI developers and medical device manufacturers to realize optimum value out of their imaging data assets. For
More news about: Flywheel
Dec 02, 2025, 09:00 ET Yuyu Pharma Announces Strategic Investment in Dalan Animal Health as Part of Accelerated Global Expansion in Animal Health
-- Yuyu Pharma announced today that it has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company advancing an innate immunity–based platform for developing vaccines for honeybees and shrimp. The investment marks a significant step in
More news about: Yuyu Pharma
Dec 02, 2025, 09:00 ET TQ Therapeutics GmbH Enters into Technology Access Agreement with Kytopen
Kytopen continues expanding its partnership footprint in Europe through a new agreement with TQ Therapeutics GmbH, a Martinsried, Germany-based biotechnology company advancing next-generation cellular therapies.TQ Therapeutics, dedicated to advancing the field of cellular
More news about: Kytopen
Dec 02, 2025, 09:00 ET Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1
cancer.In a recent pioneering study, researchers at Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, harnessed its AI-driven generative chemistry platform, Chemistry42, to design a novel, first-in-class PROTAC targeting PKMYT1, D16-M1P2,
More news about: Insilico Medicine
Dec 02, 2025, 09:00 ET Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer
MONTREAL, Dec. 2, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic
More news about: Thryv Therapeutics Inc.
Dec 02, 2025, 08:45 ET MetaVia Inc. Announces 1-for-11 Reverse Stock Split
Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par value $0.001
More news about: MetaVia Inc.
Dec 02, 2025, 08:40 ET Truist Securities strengthens Equity Research coverage in high-growth sectors
/PRNewswire/ -- Truist Securities announced today several key hires to further strengthen its Equity Research coverage across the high-growth areas of Biotechnology, Energy, Financials, Technology, and Utilities. The addition of nine seasoned professionals reinforces Truist's commitment to building top-tier
More news about: Truist Financial Corporation
Dec 02, 2025, 08:00 ET Syantra Inc. to Showcase Breakthrough Research on Immune Reprogramming in Breast Cancer at SABCS 2025
team of innovators in biomedical engineering and medicine and supported by world-leading clinicians, Syantra Inc. is a privately held, precision biotechnology company pioneering a platform to change the way cancer is detected and managed. For more information, visit
More news about: Syantra Inc.
Dec 02, 2025, 07:00 ET Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting
BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that it will
More news about: Solu Therapeutics
Dec 02, 2025, 07:00 ET Origin Agritech's Pioneering Hi3 Gene Editing Technology Awarded as Top 10 Major Progress in Chinese Agricultural Science for 2025, as Company Advances Commercialization
Science for 2025 by the Chinese Academy of Agricultural Sciences. This prestigious recognition underscores Origin's leadership in agricultural biotechnology and highlights the transformative potential of its research to drive commercial advances in crop yields and sustainability. The selection
More news about: Origin Agritech Limited
Dec 02, 2025, 07:00 ET Nanoscope Therapeutics' MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Dec 02, 2025, 06:42 ET Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR 13.75 | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
biologics, is fueling this robust market expansion. Top-tier decision-makers, including CEOs, Managers, and Directors across the pharmaceutical, biotechnology, and healthcare provider ecosystem, will find these market dynamics crucial for strategic planning, capital allocation, and maximizing shareholder
More news about: DataM Intelligence 4 Market Research LLP
Dec 02, 2025, 03:46 ET WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
with Qatar's strategic vision for biopharmaceutical advancement, this collaboration aims to drive innovation, accelerate the growth of Qatar's biotechnology sector, while jointly propel the development of a robust Middle Eastern biopharmaceutical ecosystem.Dr. Chris Chen, CEO of WuXi Biologics,
More news about: WuXi Biologics
Dec 02, 2025, 02:00 ET ZAGENO Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Life Sciences E-commerce Leadership
environment. The company's continued investment in data-driven procurement intelligence and automation has enabled it to scale effectively across global biotechnology and pharmaceutical markets.Innovation remains central to ZAGENO's operating model. Its AI-powered, end-to-end procurement platform consolidates
More news about: Frost & Sullivan